Insertional oncogenesis in gene therapy: How much of a risk?

Gene Therapy

Volumn 11, Issue 7, 2004, Pages 569-573

  Sadelain, M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; PLASMID DNA; RETROVIRUS VECTOR; VIRUS VECTOR;

ARTICLE; BONE MARROW TRANSPLANTATION; CARCINOGENESIS; CELL ONCOGENE; COMBINED IMMUNODEFICIENCY; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; GENE TRANSFER; HUMAN; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STEM CELL; TRANSACTIVATION; TRANSGENE; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MICE; MODELS, ANIMAL; MUTAGENESIS, INSERTIONAL; ONCOGENES; RISK ASSESSMENT; SEVERE COMBINED IMMUNODEFICIENCY;

MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 1842533449     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302243     Document Type: Article

References (26)

1. Nusse R et al. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984; 307: 131-136.
2. Mikkers H et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32: 153-159.
3. Suzuki T et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002; 32: 166-174.
4. Friedmana T. The future for gene therapy - a reevaluation. Ann NY Acad Sci 1976; 265: 141-152.
5. Kohn DB, et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003; 8: 180-187.
6. Hacein-Bey-Abina S et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
7. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science 2003; 299: 320.
8. Friedmann T. Gene therapy's new era: A balance of unequivocal benefit and unequivocal harm. Mol Ther 2003; 8: 5-7.
9. Hacein-Bey-Abina S et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
10. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303 (5656): 333.
11. Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001; 1: 200-208.
12. Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
13. Hacein-Bey-Abina S et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193.
14. Lantz O, Grandjean I, Matzinger P, Di Santo JP. Gamma chain required for naive CD4+ T cell survival but not for antigen proliferation. Nat Immunol 2000; 1: 54-58.
15. Royer-Pokora B, Loos U, Ludwig WD. TG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 1991; 6: 1887-1893.
16. Larson RC et al. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 1995; 11: 853-862.
17. Neale GA, Rehg JE, Goorha RM. Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8-lymphocytes in the thymus and T-cell tumors in transgenic mice. Blood 1995; 86: 3060-3071.
18. Ferrando AA et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
19. Li XC et al. IL-15 and IL-2: A matter of life and death for T cells in vivo. Nat Med 2001; 7: 114-118.
20. Pollok KE et al. Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. Hum Gene Ther 1999; 10: 2221-2236.
21. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3: 477-488.
22. Li Z et al. Murine leukemia induced by retroviral gene marking. Science 2002; 19: 296-497.
23. Bonini C et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003; 9: 367-369.
24. Rivella S, Lisowski L, Sadelain M. Globin gene transfer: A paradigm for transgene regulation and vector safety. Gene Ther Reg 2003; 2: 149-175.
25. Gerasimova TI, Corces VG. Chromatin insulators and boundaries: Effects on transcription and nuclear organization. Annu Rev Genet 2001; 35: 193-208.
26. Rivella S et al. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 2000; 74: 4679-4687.